SCHEMBL18199843

SCHEMBL18199843

Cc1cc2c(cc1C)N(c1ccccn1)C(=C1N(c3ccccn3)c3cc(C)c(C)cc3N1c1ccccn1)N2c1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.55
KDM4E B2RXH2 4/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 4/20 0.40
GAA P10253 1/20 0.40
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
CHEK1 O14757 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
ABL1 P00519 1/20 0.39
NTRK1 P04629 1/20 0.39
FYN P06241 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20071867 0.87 SMN1; SMN2 (0.43) SMN1; SMN2KDM4ECHEK1AURKADAPK3
SCHEMBL20062878 0.82 SMN1; SMN2 (0.53) SMN1; SMN2KDM4EALDH1A1GAACHEK1
SCHEMBL18365154 0.77 SMN1; SMN2 (0.46) SMN1; SMN2KDM4ENPC1ALDH1A1GAA
SCHEMBL18964725 0.76 SMN1; SMN2 (0.44) SMN1; SMN2KDM4ENPC1ALDH1A1PDCD1
SCHEMBL20681916 0.76 SMN1; SMN2 (0.44) SMN1; SMN2KDM4ENPC1ALDH1A1PDCD1
SCHEMBL20062921 0.76 KDM4E (0.33) SMN1; SMN2KDM4ENPC1ALDH1A1RAB9A
SCHEMBL20062881 0.74 RECQL (0.51) KDM4EMAPTGRIN2B
SCHEMBL19343025 0.74 HTR3A (0.47) SMN1; SMN2KDM4ENPC1ALDH1A1PDGFRB
SCHEMBL19343031 0.73 KDM4E (0.47) SMN1; SMN2KDM4ENPC1ALDH1A1GAA
SCHEMBL10999884 0.71 SMN1; SMN2 (1.00) SMN1; SMN2KDM4ENPC1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10541260-B2 Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus CANON KABUSHIKI KAISHA (JP) 2020-01-21 US disclosed
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed
WO-2016174813-A1 2,2'-BIBENZO[D]IMIDAZOLIDENE COMPOUND HAVING HETEROMONOCYCLIC GROUPS AT THE 1-, 1'-, 3- AND 3'-POSITIONS, AND ORGANIC LIGHT-EMITTING ELEMENT AND DISPLAY DEVICE CONTAINING THE SAME CANON KABUSHIKI KAISHA (JP) 2016-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 SMN1; SMN2 2289/4885KDM4E 3246/4885NPC1 3753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.